Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetin - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetin, lilly, er angivet i voksne til:behandling af depressiv disordertreatment af diabetisk perifer neuropatisk paintreatment af generaliseret angst disorderduloxetine lilly er indiceret hos voksne.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - duloxetin - neuralgia; diabetic neuropathies; depressive disorder, major; anxiety disorders - psychoanaleptics, - behandling af depressiv lidelse, behandling af diabetisk perifer neuropatisk smerte;behandling af generaliseret angst;duloxetin mylan er indiceret hos voksne.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

serb sa - amifampridin - lambert-eaton myasthenic syndrom - andre narkotika stoffer - symptomatisk behandling af lambert-eaton myasthenisk syndrom (lems) hos voksne.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

provepharm sas - methylthioniniumchlorid - methæmoglobinæmi - alle andre terapeutiske produkter - akut symptomatisk behandling af medicinske og kemiske produkter - induceret methaemoglobinaemia. methylthioninium chlorid proveblue er indiceret hos voksne, børn og unge (i alderen 0 til 17 år).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

orexigen therapeutics ireland limited - bupropion-hydrochlorid, naltrexon hydrochlorid - obesity; overweight - antiobesity preparations, excl. diætprodukter - mysimba er indiceret som et supplement til en reduceret kalorieindhold kost og øget fysisk aktivitet, for forvaltning af vægt hos voksne patienter (≥18 år) med en indledende body mass index (bmi)≥ 30 kg/m2 (fede), eller≥ 27 kg/m2 < 30 kg/m2 (overvægt) i tilstedeværelse af en eller flere vægt-relaterede co morbidities e. , type 2 diabetes, dyslipidaemia, eller kontrolleret hypertension)behandling med mysimba bør seponeres efter 16 uger, hvis patienterne ikke har tabt mindst 5% af deres oprindelige kropsvægt.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetinhydrochlorid - urininkontinens, stress - psychoanaleptics, - yentreve er indiceret til kvinder til behandling af moderat til svær stressurininkontinens (sui).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infektioner - antivirale midler til systemisk anvendelse - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

esteve pharmaceuticals, s.a. - duloxetin - anxiety disorders; depressive disorder, major; diabetic neuropathies - psychoanaleptics, - behandling af depressiv lidelse, behandling af diabetisk perifer neuropatisk smerte;behandling af generaliseret angst;xeristar er indiceret hos voksne.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - multipel sclerose - selektive immunosuppressiva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

abcur ab - amitriptylinhydrochlorid - filmovertrukne tabletter - 10 mg